Joel Picus

Joel Picus

UNVERIFIED PROFILE

Are you Joel Picus?   Register this Author

Register author
Joel Picus

Joel Picus

Publications by authors named "Joel Picus"

Are you Joel Picus?   Register this Author

75Publications

2125Reads

7Profile Views

Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer.

Authors:
Susan Slovin Syed Hussain Fred Saad Jorge Garcia Joel Picus Roberta Ferraldeschi Mateus Crespo Penelope Flohr Ruth Riisnaes Chihche Lin Harold Keer Aram Oganesian Paul Workman Johann de Bono

Clin Cancer Res 2019 Aug 21;25(15):4624-4633. Epub 2019 May 21.

The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-3212DOI Listing
August 2019

Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.

Authors:
Daniel J George Colin Hessel Susan Halabi M Dror Michaelson Olwen Hahn Meghara Walsh Joel Picus Eric J Small Shaker Dakhil Darren R Feldman Milan Mangeshkar Christian Scheffold Michael J Morris Toni K Choueiri

Oncologist 2019 Aug 9. Epub 2019 Aug 9.

Dana-Farber/Partners CancerCare, Boston, Massachusetts, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1634/theoncologist.2019-0316DOI Listing
August 2019

Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer.

Authors:
Manik Amin Monica Desai Kathryn Trinkaus Amberly Brown Andrea Wang-Gillam Benjamin Tan Joel Picus Steven Sorscher Maureen Highkin Kim Lears Albert C Lockhart

J Gastrointest Oncol 2019 Jun;10(3):412-420

Division of Oncology, University of Miami Miller School of Medicine, Miami, FL, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.21037/jgo.2019.02.01DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534727PMC
June 2019

Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.

Authors:
Petros Grivas Amir Mortazavi Joel Picus Noah M Hahn Matthew I Milowsky Lowell L Hart Ajjai Alva Joaquim Bellmunt Sumanta K Pal Richard M Bambury Peter H O'Donnell Sumati Gupta Elizabeth A Guancial Guru P Sonpavde Demiana Faltaos Diane Potvin James G Christensen Richard C Chao Jonathan E Rosenberg

Cancer 2019 Feb 20;125(4):533-540. Epub 2018 Dec 20.

Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/cncr.31817DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590473PMC
February 2019

A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database.

Authors:
Benjamin W Fischer-Valuck Jeff M Michalski Jessika A Contreras Randall Brenneman John P Christodouleas Christopher D Abraham Eric H Kim Vivek K Arora Arnold D Bullock Ruben Carmona Robert S Figenshau Robert Grubb Eric M Knoche Russell K Pachynski Joel Picus Bruce J Roth Paul Sargos Gerald L Andriole Hiram A Gay Brian C Baumann

Clin Transl Radiat Oncol 2019 Feb 12;15:38-41. Epub 2018 Dec 12.

Washington University in St. Louis, Department of Radiation Oncology, St. Louis, MO, United States.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.ctro.2018.12.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304339PMC
February 2019

Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115-125].

Authors:
Toni K Choueiri Colin Hessel Susan Halabi Ben Sanford M Dror Michaelson Olwen Hahn Meghara Walsh Thomas Olencki Joel Picus Eric J Small Shaker Dakhil Darren R Feldman Milan Mangeshkar Christian Scheffold Daniel George Michael J Morris

Eur J Cancer 2018 11 27;103:287. Epub 2018 Sep 27.

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.ejca.2018.09.022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299293PMC
November 2018

Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.

Authors:
Gwenaelle Gravis Jean-Marie Boher Yu-Hui Chen Glenn Liu Karim Fizazi Michael A Carducci Stephane Oudard Florence Joly David M Jarrard Michel Soulie Mario J Eisenberger Muriel Habibian Robert Dreicer Jorge A Garcia Maha H M Hussain Manish Kohli Nicholas J Vogelzang Joel Picus Robert DiPaola Christopher Sweeney

Eur Urol 2018 06 21;73(6):847-855. Epub 2018 Feb 21.

Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.eururo.2018.02.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010352PMC
June 2018

Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.

Authors:
Toni K Choueiri Colin Hessel Susan Halabi Ben Sanford M Dror Michaelson Olwen Hahn Meghara Walsh Thomas Olencki Joel Picus Eric J Small Shaker Dakhil Darren R Feldman Milan Mangeshkar Christian Scheffold Daniel George Michael J Morris

Eur J Cancer 2018 05 20;94:115-125. Epub 2018 Mar 20.

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.ejca.2018.02.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057479PMC
May 2018

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2).

Authors:
Jonathan E Rosenberg Noah M Hahn Meredith M Regan Lillian Werner Ajjai Alva Saby George Joel Picus Robert Alter Arjun Balar Jean Hoffman-Censits Petros Grivas Richard Lauer Elizabeth A Guancial Christopher Hoimes Guru Sonpavde Constantine Albany Mark N Stein Tim Breen Cindy Jacobs Kirsten Anderson Joaquim Bellmunt Aly-Khan A Lalani Sumanta Pal Toni K Choueiri

Br J Cancer 2018 05 16;118(11):1434-1441. Epub 2018 May 16.

Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

 Source
http://www.nature.com/articles/s41416-018-0087-9
Publisher Site
http://dx.doi.org/10.1038/s41416-018-0087-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988804PMC
May 2018

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.

Authors:
Christos E Kyriakopoulos Yu-Hui Chen Michael A Carducci Glenn Liu David F Jarrard Noah M Hahn Daniel H Shevrin Robert Dreicer Maha Hussain Mario Eisenberger Manish Kohli Elizabeth R Plimack Nicholas J Vogelzang Joel Picus Matthew M Cooney Jorge A Garcia Robert S DiPaola Christopher J Sweeney

J Clin Oncol 2018 04 31;36(11):1080-1087. Epub 2018 Jan 31.

Christos E. Kyriakopoulos, Glenn Liu, and David F. Jarrard, University of Wisconsin (UW) School of Medicine and Public Health and UW Carbone Cancer Center, Madison, WI; Yu-Hui Chen and Christopher J. Sweeney, Dana-Farber Cancer Institute; Yu-Hui Chen, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group; Christopher J. Sweeney, Harvard Medical School, Boston, MA; Michael A. Carducci, Noah M. Hahn, and Mario Eisenberger, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD; Daniel H. Shevrin, NorthShore University HealthSystem, Evanston; Maha Hussain, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; Robert Dreicer, University of Virginia Cancer Center, Charlottesville, VA; Manish Kohli, Mayo Clinic, Rochester, MN; Elizabeth R. Plimack, Fox Chase Cancer Center, Temple Health, Philadelphia, PA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Joel Picus, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO; Matthew M. Cooney, Seidman Cancer Center, University Hospitals Cleveland Medical Center; Jorge A. Garcia, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; and Robert S. DiPaola, University of Kentucky College of Medicine, Lexington, KY.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1200/JCO.2017.75.3657DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891129PMC
April 2018

Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.

Authors:
Lauren C Harshman Yu-Hui Chen Glenn Liu Michael A Carducci David Jarrard Robert Dreicer Noah Hahn Jorge A Garcia Maha Hussain Daniel Shevrin Mario Eisenberger Manish Kohli Elizabeth R Plimack Matthew Cooney Nicholas J Vogelzang Joel Picus Robert Dipaola Christopher J Sweeney

J Clin Oncol 2018 02 20;36(4):376-382. Epub 2017 Dec 20.

Lauren C. Harshman and Christopher J. Sweeney, Dana-Farber Cancer Institute, Harvard Medical School; Yu-Hui Chen, Dana-Farber Cancer Institute, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group, Boston, MA; Glenn Liu and David Jarrard, University of Wisconsin School of Medicine and Public Health and Carbone Cancer Center, Madison, WI; Michael A. Carducci, Noah Hahn, and Mario Eisenberger, Johns Hopkins University, Baltimore, MD; Robert Dreicer, University of Virginia Cancer Center, Charlottesville, VA; Jorge A. Garcia, Cleveland Clinic Taussig Cancer Institute; Matthew Cooney, University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, OH; Maha Hussain, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago; Daniel Shevrin, NorthShore University Health System, Evanston, IL; Manish Kohli, Mayo Clinic, Rochester, MN; Elizabeth R. Plimack, Fox Chase Cancer Center, Temple Health, Philadelphia, PA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Joel Picus, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO; and Robert Dipaola, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

View Article

Download full-text PDF

 Source
http://ascopubs.org/doi/10.1200/JCO.2017.75.3921
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.75.3921DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805480PMC
February 2018

Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study.

Authors:
Nilofer S Azad Anthony El-Khoueiry Jun Yin Ann L Oberg Patrick Flynn Douglas Adkins Anup Sharma Daniel J Weisenberger Thomas Brown Prakriti Medvari Peter A Jones Hariharan Easwaran Ihab Kamel Nathan Bahary George Kim Joel Picus Henry C Pitot Charles Erlichman Ross Donehower Hui Shen Peter W Laird Richard Piekarz Stephen Baylin Nita Ahuja

Oncotarget 2017 May;8(21):35326-35338

Johns Hopkins University, Baltimore, MD, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.18632/oncotarget.15108DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471058PMC
May 2017

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.

Authors:
Toni K Choueiri Susan Halabi Ben L Sanford Olwen Hahn M Dror Michaelson Meghara K Walsh Darren R Feldman Thomas Olencki Joel Picus Eric J Small Shaker Dakhil Daniel J George Michael J Morris

J Clin Oncol 2017 02 14;35(6):591-597. Epub 2016 Nov 14.

Toni K. Choueiri and Meghara K. Walsh, Dana-Farber Cancer Institute; M. Dror Michaelson, Massachusetts General Hospital Cancer Center, Boston, MA; Susan Halabi and Ben L. Sanford, Alliance Statistics and Data Center and Duke University; Daniel J. George, Duke Cancer Institute, Duke University Medical Center, Durham, NC; Olwen Hahn, Alliance Protocol Operations Office, Chicago, IL; Darren R. Feldman and Michael J. Morris, Memorial Sloan Kettering Cancer Center, New York, NY; Thomas Olencki, Ohio State University Medical Center, Columbus, OH; Joel Picus, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO; Eric J. Small, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA; and Shaker Dakhil, University of Kansas Wichita, Wichita, KS.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1200/JCO.2016.70.7398DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455807PMC
February 2017

Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study.

Authors:
Nabil Adra Costantine Albany Mary J Brames Somer Case-Eads Cynthia S Johnson Ziyue Liu Christopher A Fausel Timothy Breen Nasser H Hanna Ralph J Hauke Joel Picus Lawrence H Einhorn

Support Care Cancer 2016 07 2;24(7):2837-42. Epub 2016 Feb 2.

Division of Hematology/Oncology, Melvin & Bren Simon Cancer Center, Indiana University School of Medicine, 535 Barnhill Drive, RT 400, Indianapolis, IN, 46202, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s00520-016-3100-yDOI Listing
July 2016

Phase 1 Evaluation of [(64)Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors.

Authors:
A Craig Lockhart Yongjian Liu Farrokh Dehdashti Richard Laforest Joel Picus Jennifer Frye Lauren Trull Stefanie Belanger Madhuri Desai Syed Mahmood Jeanne Mendell Michael J Welch Barry A Siegel

Mol Imaging Biol 2016 06;18(3):446-53

Alvin J. Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8056, St. Louis, MO, 63110, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s11307-015-0912-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502796PMC
June 2016

Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.

Authors:
Andrew J Armstrong Susan Halabi Tim Eisen Samuel Broderick Walter M Stadler Robert J Jones Jorge A Garcia Ulka N Vaishampayan Joel Picus Robert E Hawkins John D Hainsworth Christian K Kollmannsberger Theodore F Logan Igor Puzanov Lisa M Pickering Christopher W Ryan Andrew Protheroe Christine M Lusk Sadie Oberg Daniel J George

Lancet Oncol 2016 Mar 13;17(3):378-88. Epub 2016 Jan 13.

Duke University and the Duke Cancer Institute, Durham, NC, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/S1470-2045(15)00515-XDOI Listing
March 2016

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

Authors:
Christopher J Sweeney Yu-Hui Chen Michael Carducci Glenn Liu David F Jarrard Mario Eisenberger Yu-Ning Wong Noah Hahn Manish Kohli Matthew M Cooney Robert Dreicer Nicholas J Vogelzang Joel Picus Daniel Shevrin Maha Hussain Jorge A Garcia Robert S DiPaola

N Engl J Med 2015 Aug 5;373(8):737-46. Epub 2015 Aug 5.

From the Department of Medicine (C.J.S.) and the Department of Biostatistics and Computational Biology (Y.-H.C.), Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston (C.J.S.); Johns Hopkins University, Baltimore (M.C., M.E.); University of Wisconsin Carbone Cancer Center (G.L., D.F.J.) and School of Medicine and Public Health (D.F.J.), Madison; Fox Chase Cancer Center, Temple University Health System, Philadelphia (Y.-N.W.); Indiana University Melvin and Bren Simon Cancer Center, Indianapolis (N.H.); Mayo Clinic, Rochester, MN (M.K.); University Hospitals Case Medical Center, Seidman Cancer Center (M.M.C.), and Cleveland Clinic Taussig Cancer Institute (J.A.G.) - both in Cleveland; University of Virginia Cancer Center, Charlottesville (R.D.); Comprehensive Cancer Centers of Nevada, Las Vegas (N.J.V.); Siteman Cancer Center, Washington University School of Medicine, St. Louis (J.P.); NorthShore University HealthSystem, Evanston, IL (D.S.); University of Michigan Comprehensive Cancer Center, Ann Arbor (M.H.); and Rutgers Cancer Institute of New Jersey, New Brunswick (R.S.D.).

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1056/NEJMoa1503747DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562797PMC
August 2015

A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma.

Authors:
May Cho Andrea Wang-Gillam Robert Myerson Feng Gao Steven Strasberg Joel Picus Steven Sorscher Chloe Fournier Gayathri Nagaraj Parag Parikh Rama Suresh David Linehan Benjamin R Tan

HPB (Oxford) 2015 Jul 20;17(7):587-93. Epub 2015 Mar 20.

Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1111/hpb.12413DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4474505PMC
July 2015

Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers.

Authors:
Laura W Goff Nilay Thakkar Liping Du Emily Chan Benjamin R Tan Dana B Cardin Howard L McLeod Jordan D Berlin Barbara Zehnbauer Chloe Fournier Joel Picus Andrea Wang-Gillam Wooin Lee A Craig Lockhart

PLoS One 2014 18;9(9):e107424. Epub 2014 Sep 18.

Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, United States of America.

View Article

Download full-text PDF

 Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0107424PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4169411PMC
June 2015

Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study.

Authors:
Jaime R Merchan Rui Qin Henry Pitot Joel Picus Glenn Liu Tom Fitch William J Maples Patrick J Flynn Briant F Fruth Charles Erlichman

Cancer Chemother Pharmacol 2015 Mar 3;75(3):485-93. Epub 2015 Jan 3.

Sylvester Comprehensive Cancer Center, University of Miami, 1475 NW. 12 Avenue. Suite 3400, Miami, FL, 33136, USA,

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s00280-014-2668-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4348698PMC
March 2015

A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies.

Authors:
Andrea Wang-Gillam Nilay Thakkar A Craig Lockhart Kerry Williams Maria Baggstrom Michael Naughton Rama Suresh Cynthia Ma Benjamin Tan Wooin Lee Xuntian Jiang Tibu Mwandoro Lauren Trull Stefanie Belanger Allison N Creekmore Feng Gao Paula M Fracasso Joel Picus

Cancer Chemother Pharmacol 2014 Aug 11;74(2):419-26. Epub 2014 Jun 11.

Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Ave., Campus Box 8056, St. Louis, MO, 63110, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s00280-014-2493-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4112045PMC
August 2014

Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer.

Authors:
Robert J Myerson Benjamin Tan Steven Hunt Jeffrey Olsen Elisa Birnbaum James Fleshman Feng Gao Lannis Hall Ira Kodner A Craig Lockhart Matthew Mutch Michael Naughton Joel Picus Caron Rigden Bashar Safar Steven Sorscher Rama Suresh Andrea Wang-Gillam Parag Parikh

Int J Radiat Oncol Biol Phys 2014 Mar;88(4):829-36

Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.

View Article

Download full-text PDF

 Source
https://linkinghub.elsevier.com/retrieve/pii/S03603016130368
Publisher Site
http://dx.doi.org/10.1016/j.ijrobp.2013.12.028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4028157PMC
March 2014

A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer.

Authors:
Roberto Pili Rui Qin P J Flynn Joel Picus Michael Millward Wing Ming Ho Henry Pitot Winston Tan Kiersten M Miles Charles Erlichman Ulka Vaishampayan

Clin Genitourin Cancer 2013 Dec 26;11(4):477-83. Epub 2013 Jul 26.

Roswell Park Cancer Institute, Buffalo, NY. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.clgc.2013.05.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102930PMC
December 2013

A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer.

Authors:
Dana E Rathkopf Joel Picus Arif Hussain Susan Ellard Kim Nguyen Chi Thomas Nydam Erin Allen-Freda Kaushal Kishor Mishra Maria Grazia Porro Howard I Scher George Wilding

Cancer Chemother Pharmacol 2013 Sep 3;72(3):537-44. Epub 2013 Jul 3.

Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s00280-013-2224-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3970811PMC
September 2013

A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma.

Authors:
Andrea Wang-Gillam Stacey Plambeck-Suess Peter Goedegebuure Peter O Simon Jonathan B Mitchem John R Hornick Steven Sorscher Joel Picus Rama Suresh Albert C Lockhart Benjamin Tan Williams G Hawkins

Invest New Drugs 2013 Jun 4;31(3):707-13. Epub 2012 Aug 4.

Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.

View Article

Download full-text PDF

 Source
http://link.springer.com/content/pdf/10.1007/s10637-012-9866
Web Search
http://link.springer.com/10.1007/s10637-012-9866-y
Publisher Site
http://dx.doi.org/10.1007/s10637-012-9866-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3760728PMC
June 2013

Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone.

Authors:
Charles J Ryan Mark Rosenthal Siobhan Ng Joshi Alumkal Joel Picus Gwenaëlle Gravis Karim Fizazi Frédéric Forget Jean-Pascal Machiels Sandy Srinivas Min Zhu Rui Tang Kelly S Oliner Yizhou Jiang Elwyn Loh Sarita Dubey Winald R Gerritsen

Clin Cancer Res 2013 Jan 7;19(1):215-24. Epub 2012 Nov 7.

University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94115, USA.

View Article

Download full-text PDF

 Source
http://clincancerres.aacrjournals.org/content/early/2012/12/
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-12-2605DOI Listing
January 2013

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.

Authors:
Cynthia X Ma Matthew J C Ellis Gina R Petroni Zhanfang Guo Shi-Rong Cai Christine E Ryan A Craig Lockhart Michael J Naughton Timothy J Pluard Christiana M Brenin Joel Picus Allison N Creekmore Tibu Mwandoro Erin R Yarde Jerry Reed Mark Ebbert Philip S Bernard Mark Watson Laurence A Doyle Janet Dancey Helen Piwnica-Worms Paula M Fracasso

Breast Cancer Res Treat 2013 Jan 15;137(2):483-92. Epub 2012 Dec 15.

Section of Breast Oncology, Division of Oncology, Department of Medicine, Washington University School of Medicine, Campus Box 8056, 660 South Euclid Avenue, St. Louis, MO 63110, USA.

View Article

Download full-text PDF

 Source
http://link.springer.com/10.1007/s10549-012-2378-9
Publisher Site
http://dx.doi.org/10.1007/s10549-012-2378-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539064PMC
January 2013

Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.

Authors:
Costantine Albany Mary J Brames Christopher Fausel Cynthia S Johnson Joel Picus Lawrence H Einhorn

J Clin Oncol 2012 Nov 20;30(32):3998-4003. Epub 2012 Aug 20.

Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, 535 Barnhill Dr, RT #473, Indianapolis, IN 46202, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1200/JCO.2011.39.5558DOI Listing
November 2012

Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer.

Authors:
John Arcaroli Kevin Quackenbush Arvind Dasari Rebecca Powell Martine McManus Aik-Choon Tan Nathan R Foster Joel Picus John Wright Sujatha Nallapareddy Charles Erlichman Manuel Hidalgo Wells A Messersmith

Cancer Med 2012 Oct 16;1(2):207-17. Epub 2012 Aug 16.

University of Colorado Cancer Center, Denver, Colorado 80045, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/cam4.27DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544442PMC
October 2012

Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782.

Authors:
J Paul Monk Susan Halabi Joel Picus Arif Hussain George Philips Ellen Kaplan Tim Ahles Lin Gu Nicholas Vogelzang William K Kelly Eric J Small

Cancer 2012 Sep 16;118(17):4139-47. Epub 2011 Dec 16.

Division of Oncology, Department of Medicine, The Ohio State University School of Medicine, Columbus, Ohio, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/cncr.26732DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558439PMC
September 2012

Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group.

Authors:
Winnie Yeo Hyun C Chung Stephen L Chan Ling Z Wang Robert Lim Joel Picus Michael Boyer Frankie K F Mo Jane Koh Sun Y Rha Edwin P Hui Hei C Jeung Jae K Roh Simon C H Yu Ka F To Qian Tao Brigette B Ma Anthony W H Chan Joanna H M Tong Charles Erlichman Anthony T C Chan Boon C Goh

J Clin Oncol 2012 Sep 20;30(27):3361-7. Epub 2012 Aug 20.

Department of Clinical Oncology, State Key Lab of Oncology in South China, Prince of Wales Hospital Shatin, Chinese University of Hong Kong, Hong Kong, China.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1200/JCO.2011.41.2395DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3438233PMC
September 2012

Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.

Authors:
Parvin F Peddi Sam Lubner Robert McWilliams Benjamin R Tan Joel Picus Steven M Sorscher Rama Suresh A Craig Lockhart Jian Wang Christine Menias Feng Gao David Linehan Andrea Wang-Gillam

JOP 2012 Sep 10;13(5):497-501. Epub 2012 Sep 10.

Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO 63110, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.6092/1590-8577/913DOI Listing
September 2012

Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.

Authors:
E Gabriela Chiorean Rashmi Ramasubbaiah Menggang Yu Joel Picus Jose A Bufill Yan Tong Nicki Coleman Erica L Johnston Colleen Currie Patrick J Loehrer

Oncologist 2012 30;17(1):13. Epub 2011 Dec 30.

Indiana University Melvin and Bren Simon Cancer Center, 535 Barnhill Drive, RT473, Indianapolis, Indiana 46202, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1634/theoncologist.2011-0253DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3267812PMC
June 2012

Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer.

Authors:
Philip A Philip Michelle R Mahoney Kyle D Holen Donald W Northfelt Henry C Pitot Joel Picus Patrick J Flynn Charles Erlichman

Cancer 2012 May 27;118(9):2424-30. Epub 2011 Sep 27.

Karmanos Cancer Institute, Detroit, Michigan 48201, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/cncr.26556DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896238PMC
May 2012

An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma.

Authors:
George P Kim Michelle R Mahoney Daniel Szydlo Tony S K Mok Robert Marshke Kyle Holen Joel Picus Michael Boyer Henry C Pitot Joseph Rubin Philip A Philip Anna Nowak John J Wright Charles Erlichman

Invest New Drugs 2012 Feb 14;30(1):387-94. Epub 2010 Sep 14.

Mayo Clinic Florida, Jacksonville, FL, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s10637-010-9532-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896232PMC
February 2012

A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer.

Authors:
Franklin M Chu Joel Picus Paula M Fracasso Robert Dreicer Zhihui Lang Brenda Foster

Invest New Drugs 2011 Aug 11;29(4):674-9. Epub 2010 Feb 11.

San Bernardino Urological Associates Medical Group, San Bernardino, CA, USA.

View Article

Download full-text PDF

 Source
http://link.springer.com/10.1007/s10637-010-9388-4
Publisher Site
http://dx.doi.org/10.1007/s10637-010-9388-4DOI Listing
August 2011

A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies.

Authors:
Paula M Fracasso Kerry J Williams Ronald C Chen Joel Picus Cynthia X Ma Matthew J Ellis Benjamin R Tan Timothy J Pluard Douglas R Adkins Michael J Naughton Janet S Rader Matthew A Arquette James W Fleshman Allison N Creekmore Sherry A Goodner Lisa P Wright Zhanfang Guo Christine E Ryan Yu Tao Eliane M Soares Shi-Rong Cai Li Lin Janet Dancey Michelle A Rudek Howard L McLeod Helen Piwnica-Worms

Cancer Chemother Pharmacol 2011 Jun 8;67(6):1225-37. Epub 2010 Aug 8.

Department of Internal Medicine, Alvin J. Siteman Cancer Center and Washington University School of Medicine, St Louis, MO, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s00280-010-1410-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102212PMC
June 2011

Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors.

Authors:
Matthew H Kulke Johanna Bendell Larry Kvols Joel Picus Rodney Pommier James Yao

J Hematol Oncol 2011 Jun 14;4:29. Epub 2011 Jun 14.

Dana-Farber Cancer Institute, Boston MA, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1186/1756-8722-4-29DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3128039PMC
June 2011

Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.

Authors:
Noah M Hahn Walter M Stadler Robin T Zon David Waterhouse Joel Picus Sreenivasa Nattam Cynthia S Johnson Susan M Perkins Mary Jane Waddell Christopher J Sweeney

J Clin Oncol 2011 Apr 21;29(12):1525-30. Epub 2011 Mar 21.

Indiana University Melvin and Bren Simon Cancer Center, Indiana Cancer Pavilion Room RT445, 535 Barnhill Dr, Indianapolis, IN 46202, USA.

View Article

Download full-text PDF

 Source
http://ascopubs.org/doi/10.1200/JCO.2010.31.6067
Publisher Site
http://dx.doi.org/10.1200/JCO.2010.31.6067DOI Listing
April 2011

A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.

Authors:
Joel Picus Susan Halabi W Kevin Kelly Nicholas J Vogelzang Young E Whang Ellen B Kaplan Walter M Stadler Eric J Small

Cancer 2011 Feb 22;117(3):526-33. Epub 2010 Sep 22.

Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/cncr.25421DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3010428PMC
February 2011

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

Authors:
Hedy Lee Kindler Donna Niedzwiecki Donna Hollis Susan Sutherland Deborah Schrag Herbert Hurwitz Federico Innocenti Mary Frances Mulcahy Eileen O'Reilly Timothy F Wozniak Joel Picus Pankaj Bhargava Robert J Mayer Richard L Schilsky Richard M Goldberg

J Clin Oncol 2010 Aug 6;28(22):3617-22. Epub 2010 Jul 6.

University of Chicago Cancer Research Center, Chicago, IL 60637-1470, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1200/JCO.2010.28.1386DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917317PMC
August 2010

Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study.

Authors:
Kerry J Williams Joel Picus Kim Trinkhaus Chloe C Fournier Rama Suresh Joan S James Benjamin R Tan

HPB (Oxford) 2010 Aug;12(6):418-26

Division of Medical Oncology, Washington University School of Medicine, Saint Louis, MI 63110, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1111/j.1477-2574.2010.00197.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028583PMC
August 2010

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:
Julie R Brahmer Charles G Drake Ira Wollner John D Powderly Joel Picus William H Sharfman Elizabeth Stankevich Alice Pons Theresa M Salay Tracee L McMiller Marta M Gilson Changyu Wang Mark Selby Janis M Taube Robert Anders Lieping Chen Alan J Korman Drew M Pardoll Israel Lowy Suzanne L Topalian

J Clin Oncol 2010 Jul 1;28(19):3167-75. Epub 2010 Jun 1.

Johns Hopkins University School of Medicine, and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1200/JCO.2009.26.7609DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4834717PMC
July 2010

Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.

Authors:
Sam J Lubner Michelle R Mahoney Jill L Kolesar Noelle K Loconte George P Kim Henry C Pitot Philip A Philip Joel Picus Wei-Peng Yong Lisa Horvath Guy Van Hazel Charles E Erlichman Kyle D Holen

J Clin Oncol 2010 Jul 7;28(21):3491-7. Epub 2010 Jun 7.

University of Wisconsin, Madison, WI 53792, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1200/JCO.2010.28.4075DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917213PMC
July 2010

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.

Authors:
Brian I Rini Susan Halabi Jonathan E Rosenberg Walter M Stadler Daniel A Vaena Laura Archer James N Atkins Joel Picus Piotr Czaykowski Janice Dutcher Eric J Small

J Clin Oncol 2010 May 5;28(13):2137-43. Epub 2010 Apr 5.

Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Ave/Desk R35, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1200/JCO.2009.26.5561DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2860433PMC
May 2010

Cardiac tamponade or hemopericardium are not associated with bleeding risk factors in consecutive patients hospitalized with noniatrogenic, pericardial effusions.

Authors:
Bryan A Faller Qin Zhang Joel Picus

Am J Hematol 2010 Apr;85(4):300-1

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/ajh.21643DOI Listing
April 2010

Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience.

Authors:
Robert J Myerson Elesyia D Outlaw Albert Chang Elisa H Birnbaum James W Fleshman Perry W Grigsby Ira J Kodner Robert S Malayapa Matthew G Mutch Parag Parikh Joel Picus Benjamin R Tan

Int J Radiat Oncol Biol Phys 2009 Oct 27;75(2):428-35. Epub 2009 Feb 27.

Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.ijrobp.2008.11.047DOI Listing
October 2009

Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.

Authors:
Katherine A Janeway Karen H Albritton Annick D Van Den Abbeele Gina Z D'Amato Paolo Pedrazzoli Salvatore Siena Joel Picus James E Butrynski Marcus Schlemmer Michael C Heinrich George D Demetri

Pediatr Blood Cancer 2009 Jul;52(7):767-71

Pediatric Oncology, Dana-Farber Cancer Institute and Department of Medicine, Children's Hospital Boston, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/pbc.21909DOI Listing
July 2009

Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies.

Authors:
Paula M Fracasso Joel Picus Jonathan D Wildi Sherry A Goodner Allison N Creekmore Feng Gao Ramaswamy Govindan Matthew J Ellis Benjamin R Tan Gerald P Linette ChauHwei J Fu Helen S Pentikis Stephen C Zumbrun Merrill J Egorin Robert E Bellet

Cancer Chemother Pharmacol 2009 Feb 15;63(3):451-8. Epub 2008 Apr 15.

Alvin J. Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA.

View Article

Download full-text PDF

 Source
http://link.springer.com/10.1007/s00280-008-0756-0
Publisher Site
http://dx.doi.org/10.1007/s00280-008-0756-0DOI Listing
February 2009

Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study.

Authors:
David W Dietz Farrokh Dehdashti Perry W Grigsby Robert S Malyapa Robert J Myerson Joel Picus Jon Ritter Jason S Lewis Michael J Welch Barry A Siegel

Dis Colon Rectum 2008 Nov 6;51(11):1641-8. Epub 2008 Aug 6.

Department of Colorectal Surgery, Cleveland Clinic, Cleveland, Ohio 44195, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s10350-008-9420-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962601PMC
November 2008

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.

Authors:
Brian I Rini Susan Halabi Jonathan E Rosenberg Walter M Stadler Daniel A Vaena San-San Ou Laura Archer James N Atkins Joel Picus Piotr Czaykowski Janice Dutcher Eric J Small

J Clin Oncol 2008 Nov 20;26(33):5422-8. Epub 2008 Oct 20.

Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

 Source
http://jco.ascopubs.org/content/26/33/5422.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2008.16.9847
Publisher Site
http://dx.doi.org/10.1200/JCO.2008.16.9847DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2651074PMC
November 2008

Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study.

Authors:
David C Linehan Marcus C B Tan Steven M Strasberg Jeffrey A Drebin William G Hawkins Joel Picus Robert J Myerson Robert S Malyapa Michael Hull Kathryn Trinkaus Benjamin R Tan

Ann Surg 2008 Aug;248(2):145-51

Department of Surgery, Barnes-Jewish Hospital/Washington University Medical Center and Siteman Cancer Center, St Louis, Missouri 63110, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1097/SLA.0b013e318181e4e9DOI Listing
August 2008

Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.

Authors:
Steven J Cohen Cornelis J A Punt Nicholas Iannotti Bruce H Saidman Kert D Sabbath Nashat Y Gabrail Joel Picus Michael Morse Edith Mitchell M Craig Miller Gerald V Doyle Henk Tissing Leon W M M Terstappen Neal J Meropol

J Clin Oncol 2008 Jul;26(19):3213-21

Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1200/JCO.2007.15.8923DOI Listing
July 2008

Activity of sunitinib in patients with advanced neuroendocrine tumors.

Authors:
Matthew H Kulke Heinz-Josef Lenz Neal J Meropol James Posey David P Ryan Joel Picus Emily Bergsland Keith Stuart Lesley Tye Xin Huang Jim Z Li Charles M Baum Charles S Fuchs

J Clin Oncol 2008 Jul;26(20):3403-10

Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1200/JCO.2007.15.9020DOI Listing
July 2008

A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer.

Authors:
Ramesh K Ramanathan Joel Picus Haralambos Raftopoulos Stephen Bernard A Craig Lockhart Gary Frenette John Macdonald Susan Melin Daniel Berg Frank Brescia Howard Hochster Allen Cohn

Cancer Chemother Pharmacol 2008 Mar 22;61(3):453-8. Epub 2007 May 22.

Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.

View Article

Download full-text PDF

 Source
http://link.springer.com/10.1007/s00280-007-0489-5
Publisher Site
http://dx.doi.org/10.1007/s00280-007-0489-5DOI Listing
March 2008

Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel.

Authors:
Tomasz M Beer Celestia S Higano Mansoor Saleh Robert Dreicer Gary Hudes Joel Picus Mark Rarick Louis Fehrenbacher Alison L Hannah

Invest New Drugs 2007 Dec 7;25(6):565-70. Epub 2007 Jul 7.

Department of Medicine, Oregon Health & Science University Cancer Institute, Portland, OR 97239, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s10637-007-9068-1DOI Listing
December 2007

Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study.

Authors:
Adam S Kibel Eli Rosenbaum Michael W Kattan Joel Picus Robert Dreicer Eric A Klein Gurkamal S Chatta Joel B Nelson Robert S DiPaola Bruce J Roth Michael S Cookson George Wilding David F Jarrard Tomasz M Beer Christopher W Ryan Daniel P Petrylak Mitchell C Benson Alan W Partin Elizabeth Garrett-Mayer Mario A Eisenberger

J Urol 2007 May;177(5):1777-81

Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri 63105, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.juro.2007.01.028DOI Listing
May 2007

Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors.

Authors:
Alexander S Ho Joel Picus Michael D Darcy Benjamin Tan Jennifer E Gould Thomas K Pilgram Daniel B Brown

AJR Am J Roentgenol 2007 May;188(5):1201-7

Division of Interventional Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 S Kingshighway Blvd., Box 8131, Saint Louis, MO 63110, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.2214/AJR.06.0933DOI Listing
May 2007

A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.

Authors:
Walter M Stadler Susan Halabi Brian Rini Marc S Ernstoff Enrique Davila Joel Picus Robert Barrier Eric J Small

Cancer 2006 Sep;107(6):1273-9

Section of Hematology/Oncology, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois 60637, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/cncr.22117DOI Listing
September 2006

Phase II study of erlotinib in patients with advanced biliary cancer.

Authors:
Philip A Philip Michelle R Mahoney Cristine Allmer James Thomas Henry C Pitot George Kim Ross C Donehower Tom Fitch Joel Picus Charles Erlichman

J Clin Oncol 2006 Jul;24(19):3069-74

Karmanos Cancer Institute, Wayne State University, 4-HWCRC, 4100 John R St, Detroit, MI 48201, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1200/JCO.2005.05.3579DOI Listing
July 2006

The role of primary chemotherapy for prostate cancer: has the time come?

Authors:
P Paula Hruska Joel Picus

Curr Urol Rep 2006 May;7(3):233-8

Siteman Cancer Center, 660 South Euclid Avenue, Campus Box 8056, St. Louis, MO 63110, USA.

View Article

Download full-text PDF

 Source
May 2006

Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480.

Authors:
Peter A Humphrey Susan Halabi Joel Picus Ben Sanford Nicholas J Vogelzang Eric J Small Philip W Kantoff

Clin Genitourin Cancer 2006 Mar;4(4):269-74

Washington University Medical Center, St. Louis, MO 63110, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.3816/CGC.2006.n.006DOI Listing
March 2006

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.

Authors:
Philip A Philip Michelle R Mahoney Cristine Allmer James Thomas Henry C Pitot George Kim Ross C Donehower Tom Fitch Joel Picus Charles Erlichman

J Clin Oncol 2005 Sep;23(27):6657-63

Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1200/JCO.2005.14.696DOI Listing
September 2005

A phase II study of alternating cycles of split course radiation therapy and gemcitabine chemotherapy for inoperable pancreatic or biliary tract carcinoma.

Authors:
Lilie L Lin Joel Picus J A Drebin David C Linehan Juan Solis Steven M Strasberg Benjamin Tan Wade L Thorstad Robert Myerson

Am J Clin Oncol 2005 Jun;28(3):234-41

Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri 63110, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1097/01.coc.0000156920.11091.12DOI Listing
June 2005

Evaluating risk factors for the development of ifosfamide encephalopathy.

Authors:
Kevin A David Joel Picus

Am J Clin Oncol 2005 Jun;28(3):277-80

Division of Medical Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1097/01.coc.0000158439.02724.5aDOI Listing
June 2005

Positron tomographic assessment of androgen receptors in prostatic carcinoma.

Authors:
Farrokh Dehdashti Joel Picus Jeff M Michalski Carmen S Dence Barry A Siegel John A Katzenellenbogen Michael J Welch

Eur J Nucl Med Mol Imaging 2005 Mar 22;32(3):344-50. Epub 2005 Feb 22.

The Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, 63110, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s00259-005-1764-5DOI Listing
March 2005

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

Authors:
Eric J Small Susan Halabi Nancy A Dawson Walter M Stadler Brian I Rini Joel Picus Preston Gable Frank M Torti Ellen Kaplan Nicholas J Vogelzang

J Clin Oncol 2004 Mar;22(6):1025-33

UCSF Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, Room A-718, San Francisco, CA 94115, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1200/JCO.2004.06.037DOI Listing
March 2004

Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study.

Authors:
Bryan P Schneider Kristen N Ganjoo David E Seitz Joel Picus Farid Fata Cindy Stoner Cynthia Calley Patrick J Loehrer

Oncology 2003 ;65(3):218-23

Division of Hematology-Oncology, Indiana University Medical Center and Walther Cancer Institute, Indianapolis, IN 46202, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1159/000074474DOI Listing
January 2004

The addition of continuous infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer.

Authors:
Christopher H Crane John M Skibber Elisa H Birnbaum Barry W Feig Anurag K Singh Marc E Delclos Edward H Lin James W Fleshman Howard D Thames Ira J Kodner Mary Ann Lockett Joel Picus Thinh Phan Anshu Chandra Nora A Janjan Thomas E Read Robert J Myerson

Int J Radiat Oncol Biol Phys 2003 Sep;57(1):84-9

Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/s0360-3016(03)00532-7DOI Listing
September 2003

Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies.

Authors:
Paula M Fracasso Luis C Rodriguez Thomas J Herzog Carole L Fears Sherry A Goodner Ramaswamy Govindan Joel Picus Janet S Rader Benjamin R Tan Matthew A Arquette

Cancer 2003 Aug;98(3):610-7

Alvin J. Siteman Cancer Center, St. Louis, Missouri 63110, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/cncr.11547DOI Listing
August 2003

Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

Authors:
Mary-Ellen Taplin Barur Rajeshkumar Susan Halabi Cary P Werner Bruce A Woda Joel Picus Walter Stadler Daniel F Hayes Philip W Kantoff Nicholas J Vogelzang Eric J Small

J Clin Oncol 2003 Jul;21(14):2673-8

University of Massachusetts Memorial Health Center, Department of Oncology, 55 Lake Ave North, Worcester, MA 01655, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1200/JCO.2003.11.102DOI Listing
July 2003

CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma.

Authors:
Adam S Kibel Brian K Suarez Jay Belani Joe Oh Raul Webster Michele Brophy-Ebbers Chan Guo William J Catalona Joel Picus Paul J Goodfellow

Cancer Res 2003 May;63(9):2033-6

Departments of Surgery, Washington University School of Medicine, St. Louis, Missouri 63110, USA.

View Article

Download full-text PDF

 Source
May 2003

11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.

Authors:
Nobuyuki Oyama Tom R Miller Farrokh Dehdashti Barry A Siegel Keith C Fischer Jeff M Michalski Adam S Kibel Gerald L Andriole Joel Picus Michael J Welch

J Nucl Med 2003 Apr;44(4):549-55

Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 S. Kingshighway Boulevard, St. Louis, MO 63110, USA.

View Article

Download full-text PDF

 Source
April 2003

Early results from a phase I/II radiation dose-escalation study with concurrent amifostine and infusional 5-fluorouracil chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.

Authors:
Robert Myerson Imran Zobeiri Elisa Birnbaum David Dietz James Fleshman Ira Kodner Joel Picus Gary Ratkin

Semin Oncol 2002 Dec;29(6 Suppl 19):29-33

Department of Radiation Oncology, and the Divisions of Colorectal Surgery and Medical Oncology, Washington University School of Medicine, St Louis, MO 63110-1001, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1053/sonc.2002.37360DOI Listing
December 2002

Severe interstitial pneumonitis associated with docetaxel administration.

Authors:
William L Read Joanne E Mortimer Joel Picus

Cancer 2002 Feb;94(3):847-53

Department of Medicine, Division of Medical Oncology at Washington University, St. Louis, Missouri, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/cncr.10263DOI Listing
February 2002